Home Mental Health & Well-Being Metformin Reduces Dementia Risk in Elderly Diabetics

Metformin Reduces Dementia Risk in Elderly Diabetics

Reading Time: 2 minutes

A new study reveals a significant dementia risk in elderly patients with type 2 diabetes mellitus (T2DM) through the use of metformin, suggesting a promising therapeutic avenue for a population vulnerable to cognitive decline.

The study investigated the association between metformin use and dementia in elderly individuals diagnosed with T2DM. It employed a time-dependent Cox hazards model to assess the impact of metformin on dementia incidence among patients aged 60 and above who were either on metformin therapy or not.

The findings were published in the journal Brain.

The results were unequivocal, showing a marked decrease in dementia risk among metformin users. An adjusted hazard ratio of 0.34 pointed to a 66% risk reduction when compared to non-users. Furthermore, the study identified a dose-dependent effect; patients adhering to a regimen of one defined daily dose (DDD) of metformin or higher exhibited even lower risks. The cumulative dose analysis reinforced these findings, showing progressively lower dementia risks with increasing metformin dosages, a clear indicator of the drug’s potential to prevent cognitive decline in this demographic.

The study tapped into Taiwan’s comprehensive National Health Insurance Research Database, enhancing the reliability of the findings through robust data and meticulous propensity score matching. This methodological rigour helped ensure that the observed benefits of metformin were not confounded by other factors, such as coexisting conditions or concurrent medication use.

This research is especially pertinent given the growing prevalence of both diabetes and dementia globally. The ageing population is particularly susceptible, making the potential impact of this study significant. Metformin, a well-established diabetes medication, could be repurposed to serve not only as a glycemic control agent but also as a preventive measure against dementia in elderly diabetic patients.

Further investigations are recommended to solidify these findings and potentially influence new guidelines in the management of elderly patients with T2DM. Prospective clinical trials could elucidate the precise mechanisms by which metformin reduces dementia risk and verify the causality of these effects.

© Copyright 2014–2034 Psychreg Ltd